

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 19, 2021**

---

**ORGANOGENESIS HOLDINGS INC.**

(Exact Name of Registrant as specified in its charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37906**  
(Commission  
File Number)

**98-1329150**  
(IRS Employer  
Identification No.)

**85 Dan Road**  
**Canton, MA**  
(Address of principal executive offices)

**02021**  
(Zip Code)

**(781) 575-0775**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Registrant's name or former address, if change since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                             | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|-------------------------------------------------|----------------------|----------------------------------------------|
| <b>Class A Common Stock, \$0.0001 par value</b> | <b>ORGO</b>          | <b>Nasdaq Capital Market</b>                 |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

---

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.*****Appointment of Prathyusha Duraibabu to Board of Directors***

On November 22, 2021, the Company announced that Prathyusha Duraibabu had been appointed by the board of directors to serve as an independent director of the Company effective as of November 19, 2021. With Ms. Duraibabu's appointment, the Company's board of directors has eight members. The board of directors also appointed Ms. Duraibabu to be a member of the audit committee of the board. Following Ms. Duraibabu's appointment, Nasdaq confirmed that the Company has regained compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires the Company's audit committee to be composed of at least three independent directors, prior to the end of the cure period afforded by Nasdaq Listing Rule 5605(c)(4)(B). Ms. Duraibabu will receive the standard cash compensation for independent directors of the Company, including retainer fees for board and committee service. In addition, she received an award of 11,340 restricted stock units, which will vest in equal annual installments over three years. Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of the Company's Class A common stock. Ms. Duraibabu will also have the benefit of the Company's standard forms of indemnification agreement and change in control retention agreement.

A copy of the press release dated November 22, 2021 announcing the appointment of Ms. Duraibabu is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.****(d) Exhibits**

| <b>Exhibit<br/>No.</b> | <b>Description</b>                                                           |
|------------------------|------------------------------------------------------------------------------|
| 99.1                   | <a href="#">Press release dated November 22, 2021.</a>                       |
| 104                    | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Organogenesis Holdings Inc.

By: /s/ Lori Freedman

Name: Lori Freedman

Title: Vice President and General Counsel

Date: November 22, 2021